EP1066061A4 - Utilisation du facteur de dispersion pour favoriser l'angiogenese - Google Patents

Utilisation du facteur de dispersion pour favoriser l'angiogenese

Info

Publication number
EP1066061A4
EP1066061A4 EP99914117A EP99914117A EP1066061A4 EP 1066061 A4 EP1066061 A4 EP 1066061A4 EP 99914117 A EP99914117 A EP 99914117A EP 99914117 A EP99914117 A EP 99914117A EP 1066061 A4 EP1066061 A4 EP 1066061A4
Authority
EP
European Patent Office
Prior art keywords
promote angiogenesis
dispersion factor
dispersion
factor
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99914117A
Other languages
German (de)
English (en)
Other versions
EP1066061A1 (fr
Inventor
Itzhak D Goldberg
Eliot M Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Long Island Jewish Medical Center
Original Assignee
Long Island Jewish Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Long Island Jewish Medical Center filed Critical Long Island Jewish Medical Center
Publication of EP1066061A1 publication Critical patent/EP1066061A1/fr
Publication of EP1066061A4 publication Critical patent/EP1066061A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP99914117A 1998-03-26 1999-03-26 Utilisation du facteur de dispersion pour favoriser l'angiogenese Withdrawn EP1066061A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4881398A 1998-03-26 1998-03-26
US48813 1998-03-26
PCT/US1999/006452 WO1999048537A1 (fr) 1998-03-26 1999-03-26 Utilisation du facteur de dispersion pour favoriser l'angiogenese

Publications (2)

Publication Number Publication Date
EP1066061A1 EP1066061A1 (fr) 2001-01-10
EP1066061A4 true EP1066061A4 (fr) 2003-01-08

Family

ID=21956589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99914117A Withdrawn EP1066061A4 (fr) 1998-03-26 1999-03-26 Utilisation du facteur de dispersion pour favoriser l'angiogenese

Country Status (6)

Country Link
EP (1) EP1066061A4 (fr)
JP (1) JP2002507584A (fr)
AU (1) AU3202999A (fr)
CA (1) CA2326053A1 (fr)
MX (1) MXPA00009440A (fr)
WO (1) WO1999048537A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1114862A3 (fr) * 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Utilitsation des polypeptides ou leurs acids nucléiques pour la diagnose ou traitement des maladies de la peau et leurs utilisation pour l'identification des substances pharmacologiquement actives
EP1176200A3 (fr) * 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Utilisation des polypeptides ou leurs acides nucléiques pour le diagnose ou traitement des maladies de la peau ou de la cicatrisation de blessures et leurs utilisations pour l'identification des substances pharmacologiquement actives
US7247620B2 (en) 2001-05-09 2007-07-24 Anges Mg, Inc. Method of treating skin wounds with vectors encoding hepatocyte growth factor
NZ544797A (en) 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
FI20065514A0 (fi) * 2006-08-16 2006-08-16 Licentia Oy Aktivoidut fibroblastit kudosvaurioiden hoitamiseksi

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007824A1 (fr) * 1995-08-29 1997-03-06 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprenant le gene hgf
WO1997012629A1 (fr) * 1995-10-05 1997-04-10 Genentech, Inc. Angiogenese amelioree au moyen du facteur de croissance des hepatocytes
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
WO1997007824A1 (fr) * 1995-08-29 1997-03-06 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprenant le gene hgf
EP0847757A1 (fr) * 1995-08-29 1998-06-17 Sumitomo Pharmaceuticals Company, Limited Medicament comprenant le gene hgf
WO1997012629A1 (fr) * 1995-10-05 1997-04-10 Genentech, Inc. Angiogenese amelioree au moyen du facteur de croissance des hepatocytes

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 199, no. 3, 1994, pages 1453 - 1460, ISSN: 0006-291X *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 222, no. 1, 1996, pages 101 - 106, ISSN: 0006-291X *
CIRCULATION, vol. 92, no. 8 SUPPL., 1995, 68th Scientific Session of the American Heart Association;Anaheim, California, USA; November 13-16, 1995, pages I748, ISSN: 0009-7322 *
CIRCULATION, vol. 94, no. 8 SUPPL., 1996, 69th Scientific Sessions of the American Heart Association;New Orleans, Louisiana, USA; November 10-13, 1996, pages I463, ISSN: 0009-7322 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994, WATANABE SUMIO ET AL: "Hepatocyte growth factor accelerates the wound repair of cultured gastric mucosal cells.", XP002219961, Database accession no. PREV199497222079 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, VAN BELLE ERIC ET AL: "Scatter factor stimulates angiogenesis in a rabbit model of hindlimb ischemia.", XP002219968, Database accession no. PREV199698586061 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, HAYASHI SHIN-ISHIRO ET AL: "Hypoxia down-regulated a novel angiogenic growth factor, hepatocyte growth factor (HGF) in human vascular cells, and transfection of HGF gene rescued endothelial cell death induced by hypoxia.", XP002219967, Database accession no. PREV199799303954 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, KATO KAZUYA ET AL: "Effect of hepatocyte growth factor on the proliferation of intrasplenically transplanted hepatocytes in rats.", XP002219959, Database accession no. PREV199699010900 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, LATERRA JOHN ET AL: "Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo.", XP002219957, Database accession no. PREV199799551720 *
DATABASE MEDLINE [online] BUSSOLINO ET AL: "Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth", XP002219958, Database accession no. NLM1383237 *
DATABASE MEDLINE [online] KIM ET AL: "Enhanced survival of transgenic hepatocytes expressing hepatocyte growth factor in hepatocyte tissue engineering", XP002219960, Database accession no. NLM9123555 *
GRANT D S ET AL: "SCATTER FACTOR INDUCES BLOOD VESSEL FORMATION IN VIVO", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 90, March 1993 (1993-03-01), pages 1937 - 1941, XP002935422, ISSN: 0027-8424 *
LABORATORY INVESTIGATION, vol. 76, no. 4, 1997, pages 565 - 577, ISSN: 0023-6837 *
ROSEN E M ET AL: "SCATTER FACTOR AND ANGIOGENESIS", ADVANCES IN CANCER RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 67, 1995, pages 257 - 279, XP000615858, ISSN: 0065-230X *
See also references of WO9948537A1 *
THE JOURNAL OF CELL BIOLOGY, vol. 119, 1992, pages 629 - 641 *
TRANSPLANTATION PROCEEDINGS, vol. 29, 1997, pages 858 - 860 *
UEDA H ET AL: "IN VIVO GENE TRANSFECTION OF HEPATOCYTE GROWTH FACTOR ATTENUATES ISCHEMIA-REPERFUSION INJURY IN THE HEART: EVIDENCE FOR A ROLE OF HGF IN ENDOGENOUS MYOCARDIAL PROTECTION", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 96, no. 8, 1997, pages 1619, XP002936330, ISSN: 0009-7322 *

Also Published As

Publication number Publication date
JP2002507584A (ja) 2002-03-12
CA2326053A1 (fr) 1999-09-30
WO1999048537A1 (fr) 1999-09-30
EP1066061A1 (fr) 2001-01-10
MXPA00009440A (es) 2003-04-22
AU3202999A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
SE9704409D0 (sv) Sätt att dynamiskt ändra längden av miniceller
DE69731674T8 (de) Silencieux d'aspiration pour compresseur
MA24391A1 (fr) Progesterone pour traiter ou reduire l'ischemie
EP0934305A4 (fr) Antagonistes de l'integrine
FR2753900B1 (fr) Compositions pour le maquillage des yeux
DE69506552D1 (de) Seife zusammensetzung
FR2798590B1 (fr) Utilisation de l'alverine pour diminuer les rides
EP0946164A4 (fr) Antagonistes de l'integrine
DK0869898T3 (da) Flydebeklædningsgenstand
FR2785155B3 (fr) Structure d'element decoratif pour cheveux
AU2683899A (en) The use of bjerknes forces to manipulate contrast agents
FR2793766B1 (fr) Pale pour voilure tournante d'aeronef
ID24940A (id) Pemakaian ketolida-ketolida untuk pencegahan komplikasi trombotik arteri mengenai aterosklerosis
KR980000595U (ko) 우산탈수장치
FR2766334B1 (fr) Installation pour parer les brocolis
FR2775186B1 (fr) Utilisation d'extraits bacteriens de la famille des pseudomonadacees comme agents cosmetiques
DE69709755D1 (de) Den oberteil von flaschen untergreifender träger
EP0698921A3 (fr) Structure en coudres adaptée pour l'intégration de modul co-cuite
FR2778564B1 (fr) Utilisation de composes reduisant l'apoptose
KR980003110U (ko) 스키머(skimmer)의 유수 유도 개폐장치
KR960016322U (ko) 두건이 달린 수건
FR2745908B1 (fr) Interferometre pour l'etude du postulat relativiste
KR960014659U (ko) 욕조용 탕수혼합수전의 연결구 구조
LV11766A (lv) Devejs speka merisanai
KR960005100U (ko) 슬래그 혼입방지 구조

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001024

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20021121

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROSEN, ELIOT, M.

Inventor name: GOLDBERG, ITZHAK, D.

17Q First examination report despatched

Effective date: 20040220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040702